Dacarbazine Disease Interactions
There are 4 disease interactions with dacarbazine.
Antineoplastics (applies to dacarbazine) infections
Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.
Dacarbazine (applies to dacarbazine) hepatic dysfunction
Major Potential Hazard, Low plausibility. Applicable conditions: Liver Disease
The pharmacokinetic disposition of dacarbazine may be altered in patients with hepatic impairment. Hepatotoxicity, including hepatic vein thrombosis and hepatocellular necrosis, have been reported. Patients should be instructed to immediately report any sign or symptoms of liver dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia. Therapy with dacarbazine should be administered cautiously in patients with or predisposed to compromised hepatic function.
Dacarbazine (applies to dacarbazine) myelosuppression
Major Potential Hazard, High plausibility. Applicable conditions: Fever, Bone Marrow Depression/Low Blood Counts, Bleeding
Dacarbazine is myelosuppressive, primarily affecting leukocytes and thrombocytes, although anemia occasionally occurs. Deaths due to myelosuppression have been reported. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Therapy with dacarbazine should be withheld or extreme caution exercised when administered in patients whose bone marrow reserve may be severely depressed. Close clinical monitoring of hematopoietic function is recommended.
Dacarbazine (applies to dacarbazine) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
Dacarbazine is partially eliminated by the kidney via renal tubular secretion. Approximately 40% of dacarbazine is eliminated unchanged in the urine. The half-life of dacarbazine may be increased in patients with renal impairment. Rare reports of unspecified, severe renal toxicity has been noted. Therapy with dacarbazine should be administered cautiously to patients with compromised renal function. Clinical monitoring of renal function is recommended.
Dacarbazine drug interactions
There are 274 drug interactions with dacarbazine.
More about dacarbazine
- dacarbazine consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- Drug class: alkylating agents
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.